CAS: 854847-61-3

HLY78, a Wnt/β-catenin activator, enhances Axin-LRP6 binding by targeting Axin's DIX domain.

HLY78

HLY78 is a monoclonal antibody that targets the prostate cancer cell surface antigen, Prostate Specific Membrane Antigen (PSMA). This antibody has been shown to inhibit growth of prostate cancer cells in vitro and to suppress the growth of prostate tumors in vivo. HLY78 has also been shown to inhibit signal pathways, such as the phosphatidylinositol 3-kinase (PI3K) pathway, which may lead to decreased tumor progression and metastasis. HLY78 has been shown to bind to PSMA on prostate cancer cells with high affinity and specificity, thereby blocking the interaction between PSMA and its receptor. This binding inhibits the activation of PI3K and other signal pathways, leading to decreased tumor progression and metastasis. Hly78 is a monoclonal antibody that targets the prostate cancer cell surface antigen, Prostate Specific Membrane Antigen (PSMA). This antibody has been shown to inhibit growth of prostate cancer cells